Status:
TERMINATED
Diamondback in Peripheral Vascular Disease
Lead Sponsor:
Arkansas Heart Hospital
Collaborating Sponsors:
Abbott Medical Devices
Conditions:
Peripheral Vascular Diseases
Critical Limb Ischemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, nonrandomized, single-arm study using CSI Orbital Atherectomy System in patients with PAD (total occlusions or significant stenosis). Patients will be enrolled if they have clau...
Detailed Description
Orbital atherectomy (OA) is one of the most commonly used modalities for the treatment of obstructive femoral-popliteal PAD, especially in patients with large and calcified atherosclerotic plaques, ei...
Eligibility Criteria
Inclusion
- • Patient with lower extremity claudication and PAD due to significant SFA or below the knee stenosis (50%≤99%) or total occlusions (100%) that affects the quality of life despite medical therapy.
- Evidence of significant SFA or below the knee disease involving the most symptomatic limb by noninvasive vascular testing with the use of the following:
- ABI: \<0.9 (If ABI\>1.4, SFA systolic acceleration time should be \> 140 milliseconds);
- TBI: \<0.6;
- Computed Tomographic Angiography (CTA) confirming at least a 50% SFA stenosis with moderate to severe calcification; or
- Magnetic Resonance Angiography (MRA) confirming at least a 50% SFA or below the knee stenosis with moderate to severe calcification.
- At least one patent, non-treated below the knee vessel.
- Male and female patients that are ≥ 18 years of age.
- Subject has been advised of the beneficial effects of smoking cessation and regular exercise but must not be in the process of changing their smoking status at the time of screening. Patients may resume or increase exercising as an effect of post procedurally improved lower limb perfusion.
- Peak Walking Time (PWT) limited only by claudication.
- Willingness to participate in the study, documented by signed, written informed consent.
Exclusion
- • Planned amputation.
- Any planned/scheduled revascularization procedures ≤ 30 days after baseline procedure.
- Prior lower extremity revascularization ≤ 30 days before baseline procedure.
- The target lesion is an in-stent restenosis.
- Infra-popliteal disease involving the last remaining vessel.
- Patients with a creatinine clearance \< 30mL/min.
- Patients with known bleeding disorders.
- Patients with known active pathological bleeding.
- Patients with known hypersensitivity to acetylsalicylic acid, clopidogrel bisulfate, ticagrelor, Aspirin, or other antiplatelets/anticoagulants.
- Patients with known history of intracranial hemorrhage at any time, GI bleed in the past 6 months, or major surgery within the past 30 days.
- Patients with known ischemic stroke during the past 3 months.
- Patients with known severe liver disease.
- Patient with known history of congestive heart failure (CHF) with an LVEF of \< 30%.
- Patients considered being at risk of bradycardic events unless treated with a permanent pacemaker.
- Female patients with known pregnancy, breast feeding, or intend to become pregnant during the study period (all female patients 55 years and younger, without a history of hysterectomy must have a pregnancy test prior to PPI at baseline and at 6 months).
- Concern for inability of the patient to comply with study procedures and/or follow up (e.g., alcohol or drug abuse).
Key Trial Info
Start Date :
August 8 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03455374
Start Date
August 8 2017
End Date
May 13 2019
Last Update
June 27 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
2
Arkansas Site Management Services LLC
Little Rock, Arkansas, United States, 72211